Brennan Jonathan P, Southworth Richard, Medina Rodolfo A, Davidson Sean M, Duchen Michael R, Shattock Michael J
Cardiac Physiology (Cardiovascular Division), The Rayne Institute, St Thomas' Hospital, King's College London, SE1 7EH, UK.
Cardiovasc Res. 2006 Nov 1;72(2):313-21. doi: 10.1016/j.cardiores.2006.07.019. Epub 2006 Jul 29.
Both K(ATP) channel opening drugs and ischaemic preconditioning have been suggested to protect the ischaemic heart by acting on K(ATP) channels in the inner mitochondrial membrane, uncoupling the proton gradient and partially dissipating the mitochondrial membrane potential. The aim of these studies was to use low concentrations of FCCP, a mitochondrial protonophore, to bypass the mitochondrial K(ATP) channel and partially uncouple the mitochondria and establish whether this activates protective pathways within the rat heart analogous to K(ATP) channel openers or preconditioning.
Isolated, Langendorff-perfused rat hearts were subjected to 25 min global zero-flow ischaemia and functional recovery assessed. Hearts were pretreated with FCCP (30-300 nM) in the presence or absence of glibenclamide (1 microM), 5-hydroxydecanoate (5-HD: 100 microM), N-acetyl cysteine (4 mM), or N-2-mercaptopropionyl glycine (1 mM). The metabolic consequences of FCCP perfusion in isolated hearts were studied using (31)P NMR, and reactive oxygen species (ROS) production was measured using DCF fluorescence in isolated rat ventricular myocytes.
FCCP exerted a dose-dependent cardioprotective effect, with 100 nM FCCP being the optimal concentration. This effect could not be blocked by glibenclamide or 5-HD, but was completely attenuated by N-acetyl cysteine and N-2-mercaptopropionyl glycine. Perfusion with FCCP (100 nM) did not deplete bulk ATP during the pretreatment period but significantly depleted phosphocreatine. In ventricular myocytes, FCCP caused an antioxidant-sensitive increase in ROS production but diazoxide was without effect.
In the isolated rat heart, partial mitochondrial uncoupling with low-dose FCCP significantly improves post-ischaemic functional recovery via a ROS-dependent pathway. This cardioprotection is not mediated via the depletion of cellular ATP or mitochondrial K(ATP) channel activation.
已有人提出,K(ATP)通道开放药物和缺血预处理均通过作用于线粒体内膜上的K(ATP)通道、使质子梯度解偶联并部分耗散线粒体膜电位来保护缺血心脏。这些研究的目的是使用低浓度的FCCP(一种线粒体质子载体)绕过线粒体K(ATP)通道并使线粒体部分解偶联,以确定这是否会激活大鼠心脏内类似于K(ATP)通道开放剂或预处理的保护途径。
对离体的、采用Langendorff灌流的大鼠心脏进行25分钟的全心零流量缺血,并评估其功能恢复情况。在有或无格列本脲(1 μM)、5-羟基癸酸(5-HD:100 μM)、N-乙酰半胱氨酸(4 mM)或N-2-巯基丙酰甘氨酸(1 mM)存在的情况下,用FCCP(30 - 300 nM)对心脏进行预处理。使用(31)P NMR研究FCCP灌注离体心脏后的代谢后果,并使用DCF荧光法测量离体大鼠心室肌细胞中的活性氧(ROS)生成情况。
FCCP发挥了剂量依赖性的心脏保护作用,100 nM的FCCP为最佳浓度。这种作用不能被格列本脲或5-HD阻断,但被N-乙酰半胱氨酸和N-2-巯基丙酰甘氨酸完全减弱。在预处理期间,用FCCP(100 nM)灌注并未耗尽大量ATP,但显著消耗了磷酸肌酸。在心室肌细胞中,FCCP导致ROS生成增加且对抗氧化剂敏感,但二氮嗪无此作用。
在离体大鼠心脏中,低剂量FCCP使线粒体部分解偶联可通过依赖ROS的途径显著改善缺血后功能恢复。这种心脏保护作用不是通过细胞ATP耗竭或线粒体K(ATP)通道激活介导的。